188 results on '"Blue, Brandon"'
Search Results
2. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
3. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
4. Enabling remote quantum emission in 2D semiconductors via porous metallic networks
5. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma
6. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
7. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
8. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
9. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
10. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
11. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
12. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience
13. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
14. Guarding the Heart in an Era of “Tachy-CAR-T”
15. STM Tip-Induced Switching in Molybdenum Disulfide-Based Atomristors
16. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas
17. Roundtable on Black in cancer research and oncology
18. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
19. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
20. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
21. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
22. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
23. Enabling remote quantum emission in 2D semiconductors via porous metallic networks
24. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)
25. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience
26. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
27. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
28. Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy
29. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
30. Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
31. Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
32. Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
33. Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
34. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
35. Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
36. Observation of Wigner cusps in a metallic carbon nanotube
37. Scanning tunneling microscopy and spectroscopy of NiTe2
38. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access
39. IBCL-666 The Natural History of Asymptomatic (Smoldering) Waldenström Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation
40. The Natural History of Asymptomatic (Smoldering) Waldenström Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation
41. The effect of race, employment, and poverty on outcomes in chimeric antigen receptor therapy for DLBCL patients.
42. Race‐based differences in routine cytogenetic profiles of patients with multiple myeloma
43. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
44. Understanding Physician Referral for Chimeric Antigen Receptor T-Cell Therapy
45. Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
46. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA
47. Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
48. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
49. Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma
50. Clinical presentation and outcome of patients with AL amyloidosis requiring salvage therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.